Media
Corgentech Files Registration Statement for Initial Public Offering
(SOUTH SAN FRANCISCO, Calif., December 4, 2003) -- Corgentech Inc. announced today that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission for an initial public offering of shares of its common stock.
The underwriters of the offering will be Credit Suisse First Boston and Lehman Brothers, acting as joint book-running managers, and CIBC World Markets and U.S. Bancorp Piper Jaffray, acting as co-managers. The number of shares to be offered and the price range for the offering have not yet been determined.
The offering will be made only by means of a prospectus. When available, a copy of the preliminary prospectus relating to the offering may be obtained from the prospectus department of either Credit Suisse First Boston LLC (One Madison Avenue, New York, New York 10010; 212-325-2580) or Lehman Brothers Inc., Prospectus Department (c/o ADP Financial Services, Integrated Distribution Services, 1155 Long Island Avenue, Edgewood, New York 11717; 631-254-7106).
A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.
About Corgentech Inc.
Corgentech Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of a new class of therapeutics called transcription factor decoys, or TF Decoys, for the treatment of cardiovascular disease, inflammatory disease, such as arthritis, and cancer.
